Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
so are you claiming that july is the last incoming and then they can reverse after that?
regardless of whether or not they can do that why would anyone be perilously short with the history of this company. surely nobody could discount what they might try.
on another note since taran is private, lets say they get a voucher for x dollars. ( i doubt it)
do they have to report it or would it be reported by default?
jay if you are correct and lenzilumab has all this unbelievable potential , what makes you think the market didn’t realize it long ago like you
Please take further notice that on March 19, 2024, the Court entered an order (the “Bar Date
Order”)2
establishing: (i) April 22, 2024 at 5:00 p.m. (prevailing Eastern Time) (the “General
Bar Date”) as the last date and time for each person or entity to file a Proof of Claim in this
Chapter 11 Case, including claims arising under section 503(b)(9) of the Bankruptcy Code;
(ii) April 22, 2024 at 5:00 p.m. (prevailing Eastern Time) (the “Administrative Claims Bar
Date”) as the deadline for each person or entity that asserts a request for payment of administrative
expense claims (collectively, the “Administrative Claims”) arising between the Petition Date and
February 20, 2024 (the “Administrative Claims Deadline”) to file a request for payment of such
Administrative Claims; and (iii) and July 1, 2024 at 5:00 p.m. (prevailing Eastern Time)
(the “Governmental Bar Date”) as the date by which all governmental units holding claims
(whether secured, unsecured priority, or unsecured non-priority) that arose (or are deemed to have
arisen) before the Petition Date must file Proofs of Claim, including claims for unpaid taxes,
whether such claims arose from prepetition tax periods or prepetition transactions to the Debtor
were a party https://document.epiq11.com/document/getdocumentbycode?docId=4309765&projectCode=HUM&source=DM
If they would have recalled the shares before BK, they would have had to pay back the 40 million they owed. The share call back is speculative but what I don;t understand is why not declare liquidation? Why keep the share structure in place
You could be absolutely right, dlog.
Because I believe in the huge potential of lenz to effectively treat, and then to possibly prevent, a huge number of indications, and also because I believe in the good character of our management, I have made it my objective to try to understand what this management team is doing to get their lenz into the market. And I have shared my conclusions and opinions here.
Yes, there would have been benefit with an earlier recall of the loaned shares. It would have amounted to a blip on the radar. Even if it staved off the bankruptcy, the momentum would not have been sustained, without news leading to our ability to generate a revenue stream.
In the US, and in the UK, we're looking for regulatory approval for lenz to treat covid. That would cause the FDA and the MHRA to destroy the markets for Pfizer and Moderna, who provide the vast majority of the regulators' operating funds. It would also threaten the value of the intellectual property OWNED BY THE REGULATORS in the Pfizer and Moderna mRNA vaccines. Regulators would be slicing their own financial throats by approving Humanigen's lenzilumab, and the Novavax vaccine that uses lenz as an enhancement.
We have to capitalize on the IND authorization by having partners use lenz under IND for their vaccine and CAR-T products. We also need to exploit our opportunity for regulatory approval of lenz from Australia, to treat CMML. It's almost "game-over" for the attempts to deny our revenue stream. We will prevail. It would be an absolute catastrophe to use mRNA technology to fight a virus that could have 100% mortality, such as the Pangolin Coronavirus.
We need to see regulatory approval of lenz, which is most likely to first come from Australia. And the flood gates will then be open.
And that's when management can recall their loaned shares to the fullest monetary advantage.
seems to me if what you believe is true, the “share recall” could have solved all the company problems.
there would have been no need for any BK
its just more fantasy just like novavax is a fantasy.
Are you insane?
what martee did do with kalobios pissed off the bowel of wall street . he secretly purchased the float , then stopped loaning shares which caught these nice folk with pants down .
he did what is pretty much forbidden on wall street . he ripped off the crooks.
that action only added to his pariah image.
fast forward to Cam- he would NEVER TRY TO PULL THAT KIND OF STUNT. even if he could. he bows to the street
jay talks arcanely about the special share structure he cant clearly explain, and uses a share number that popped up for a day on this site of all places.
there are no shares to recall here. all the institutional money shorted this to zero to extract as much as they could make back
there are so many ways for pros to grift money out of pennies, and they fight for the proceeds with management, like dale who made a fortune off this scam
the one thing cam talks about post apocalypse has nothing to do with the shareholders he deserted and desecrated .
theres a reason two retail were able to purchase 10% of company for a few thousand bucks. lol
I don't think it had anything to do with calling shares or with kalobios. He was just a crook....so yes he made enemies.
Those .0003's make my account look pretty Green. My average is at .00027.
im glad your optimistic.
i believe this is toast
that barliant guy helped him scam us too with the slick BK
shkreli went to jail with the enemies he made recalling shares lol
there will be no such thing here
I think Shkreli executed the recall of the loaned shares to re-pay his hedge fund clients from the short squeeze proceeds. Regardless of whether I over-estimated his character, or not, our short squeeze proceeds will go to funding our operational requirements, and likely regain compliance with OTC requirements for quotation, before moving back to Nasdaq.
Novavax's financial condition can do a complete reversal, if their prototype vaccine incorporated a lenz enhancement.
Anyway, once the pieces are in place, then will be the time to evaluate what "...cam has shown..."
My tenacity is just a reflection of my conviction in the character of our management, and in the safety and efficacy of lenz, which is poised to be enthusiastically embraced by the medical community, for a whole host of indications. We've never been stronger, but we will be.
You and I both posted here initially in 2015, so your opinion of me is based on a pretty complete awareness of my conclusions. I may have been able to make a more complete case, for instance, in regards to the share recall, perhaps if those records weren't sealed, and if we saw the charges against Dale's entities. The SEC didn't waste any time after the Kalobios squeeze, and charges against Dale's entities go all the way back to the very time that we became Humanigen. Still, I think Dale very likely won his Appeal. The share structure was managed meticulously, and I believe we will see a float of ~229M shares, which will cause a monster short squeeze when the loaned shares are recalled.
You are correct in saying that an opportunity with Novavax exists only in my head. There's been no sign of it otherwise. But they are the prime candidate that would qualify to use our lenz/vaccine patent, and I think they will have that opportunity as the deadly mRNA vaccines are losing market share, even before the Humanigen/Novavax product comes to market.
Hopefully, we have a pretty decent revenue stream from Gracell, and also hopefully we will be able to snag Tera-Immune, especially if Sanofi expands our opportunity to use the Treg process. Sanofi has always had a complimentary product line to Humanigen, and I look forward to the spin-off of their healthcare business. Don't discount that potential. They were here even before we showed up in 2015.
Up to 15 cases of measles in Chicago now. Two different migrant shelters are impacted as well as a case in the schools
Considering that many of the people entering the US illegally are coming from countries that do NOT have vaccination rates better than 70% (Except for China, which is at 99%), that means that at least 30%, OR MORE, of their populations are NOT vaccinated. While you may not like Tucker Carlson, and feel it neceassry to name call those that may wish to watch or listen to his programs, you cannot ignore the very real likelihood that the resurgence of measles in this country can be, in large part, directly attributed to so many unvaccinated people crossing our borders.
"I don't think there is any way in hell that Pfizer and Moderna will stay in the covid vaccine market past the end of the year, and run the risk of putting their mRNA vaccines into the market, without immunity from prosecution."
We'll see if that proves to be the case. It would definitely mean admitting defeat on the course that Pfizer, Moderna, and the FDA have been mandating.
And in the UK, I see what could be further recognition that the wrong covid treatment course was chosen. The UK announced that the fourth module of their national Covid-19 Inquiry will be rescheduled.
start at the beginning. this section of information concludes at the 4 minute mark, and goes on to an important discussion of 'Disease X.'
I believe the price movement has been very weird going back to the trials. Even before BK I never understood why CYDY traded higher than HGEN. HGEN had an actual product. I can guess that extra shares are out there or the stock price has been manipulated but I do not know for sure. Total speculation in trying to piece things together
Do you truly believe that there are not millions of shares in a shorted situation at this time? Doesn't matter who loaned them......they will automatically be called in when a merger happens and the price will skyrocket as the crooks scramble to cover. They are/were taking a calculated chance that bankruptcy would destroy Humanigen and they would NEVER have to cover (giving them free, untaxable money)......NOW????
A reverse merger makes sense if short shares are recalled. Taran becomes a publicly traded company with a lot of cash on hand. But we do not know if any shares were loaned out to recall. It does seem like a long shot, however
I PRAY YOU ARE RIGHT!!! This would be such a Huge Blessing for Me!!!
It's not complicated. A reverse merger makes Taran a public company (able to sell stock to raise money) and it calls all of Humangien's counterfeit and illegal short shares. Sounds very doable to me. Humanigen is now a gold mine for Cameron.... and for us.....all thanks to the shorting crooks who claim they are doing a service for the markets.....while all the time trying to destroy and drive into bankruptcy a small company trying to do a service to humanity.....so that they never have to pay taxes on their ill-gotten gains.
Tell it to the bankruptcy court judge. He obviously saw no cause to convert the case to CH7, which he should have done, if you guys are right about how worthless we are.
But you're right about the reaction we should have gotten from the clinical trials. The reaction we got from the Top Line Data should have indicated what to expect from the FDA decision.
All the assets including inventory and equity in subsidiaries go to Taran . Unless we somehow are enamored with the name there is nothing of value except cash of 2.5 mil less chapter 11 expenses . They need that’s cash to settle any unsettled debts from chapter 11 debts . hope cash there , is enough to give us multiples on the recall of an unknown number of shorted shares . If we are expecting a miracle , it should have happened with the trials . Covid trials had bankrupted the company . To somehow reuse that data and make money is …. I think you need something stronger to smoke .i am a positive person but even I can’t get that high ! Cameron pulled the carpet from right under our feet . Reverse merger ? What is Tarans benefit , unless they want the balance cash from humanigen that they gave . I doubt there will be any left after they give themselves a fat bonus for the APA .
The powers that be are losing control. Patients and doctors are not buying the mRNA vaccines as they were. It's time for lenz.
The $10K was the company's stated price for the therapeutic infusions.
I wondered about the cost of lenz, if used as a vaccine enhancement. Dosage and formulation of lenz for that application may be substantially less.
I would love to see you be proven right, but unfortunately the powers to be want us to get as much mRNA vaccines as possible. It's about getting the nano tech into us:
The vascular surgeon did two atherectomies in a procedure last year, leaving me with a long stent. I was supposed to have a follow-up visit with him last week, which was contingent on how much that was going to cost. The doctor's staff told me last week how much the insurance wouldn't pay, and I rescheduled the appointment. And yes, for the first time in my life, I began taking a few prescription drugs last year, as you surmised.
I hate to leave the house, but I have always hated leaving the house. It's just that this time, I drag my feet getting ready, until I finally succeed in becoming too late to go anywhere.
jay there will be no share recall
pure fantasy
lenz will never treat covid, we have an abundance of chowder heads who like the vaccines
novavax doesn’t even know who taran or humanigen are
how you believe a drug they tried to say was valued at 10k per treatment could ever be used as a vaccine prophylactic is way beyond fantasy , maybe hallucinating
sorry
DTG, I don't interpret Durrant's comments as you do. I think the key is in what was not said. It does not consider the reasons why the bankruptcy court judge is discharging the case as a CH11. I'm glad that you recognize the potential of a looming recall of the loaned shares. But the magnitude of that impact, when it comes, will be far from some pittance for the poor Humanigen shareholders.
I'm not discounting the reasonableness of anyone who comes to that deduction. In fact, I recognize that my own estimation of the value of lenz in treating covid needs more than just an appreciation of the safety and efficacy of the product. The value I attach to lenz for covid requires a degree of necessity that that value comes to light. Now, that necessity is becoming exposed, by the deadly health effects of the mRNA vaccines. The medical community needs to see that lenz has a role in helping to prevent covid pneumonia infection, without contributing to excess deaths overall. They need to see that lenz is the best therapeutic capable of safely curing the infection, and that lenz can prevent future reoccurrences of covid.
I think the stage is set to showcase lenzilumab's role in fighting covid, both as a prophylaxis, and as a therapeutic. And I think Novavax may become the partner we need to establish control of the worldwide covid market. I think those steps must be taken, for the protection of the populace. And I believe those steps are being taken.
I still wish you are correct here and that we get something to cause a recall of those loaned shares. So I haven't given up here just yet, even though it doesn't look good for us at this point in time.
I'm sorry Jay, but this was posted by Cameron himself:
Following an amazing eight-year, hugely intense journey at Humanigen, we recently closed the acquisition of the Humanigen assets and placing them in Taran, a Delaware C-corporation, with UK and Australian wholly-owned subsidiaries.
Taran is focused on helping bring life-saving medicines to patients, including lenzilumab ("LENZ") and ifabtotuzumab ("IFAB") in various leukemias, Graft vs. Host Disease and cancer, with possibilities in multiple other areas of high unmet medical need.
Taran is the Welsh word for "thunder". My wife bred a beautiful male Welsh cob foal, who was born during a thunderstorm and named him Taran.
The choice of Taran for the new company name honors her memory, as well as the beauty, pride and strength of the Welsh people and language and the physical and mythical power of thunder as an unstoppable force.
It's been a year since Humanigen filed a 10-Q, which indicated a cash balance of about $3.1M.
pg 4
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923007002/hgen-20230331.htm
The bankruptcy filing claimed a cash balance of only about $500K.
https://www.reuters.com/business/healthcare-pharmaceuticals/covid-19-treatment-developer-humanigen-files-chapter-11-bankruptcy-2024-01-04/#:~:text=Jan%204%20(Reuters)%20%2D%20Drug,for%20its%20COVID%2D19%20treatment.
And we know the bankruptcy judge had approved of Taran providing $1M in financing, ahead of the closing of the bankruptcy, when they paid an additional $1M.
So we could have about $4M of additional lenz either produced, or scheduled to be produced. Starting a revenue stream is a required objective for Humanigen/Taran, and with Durrant investing millions into the operation at this point, I don't see why I should be worried, if he isn't.
The frenemies who, along with the FDA, kept us out of the market, are themselves now financially threatened. People are waking up to the harm inflicted by the mRNA vaccines. That is resulting in substantial revenue declines for Pfizer and Moderna, and steep cuts in FDA funding operations from Big Pharma, including licensing fees required of Big Pharma to the FDA.
If we get Novavax to use lenz under the approved IND authorization, to enhance the efficacy their vaccine with our patented formulation, we will own the covid market. Investors will be clamoring to buy shares, and Humanigen owns ~90% of the Outstanding Shares. But prospective buyers will have to compete with brokerages who will be faced with a recall of the loaned shares.
And that is just looking at the covid scenario, which seems more likely than ever, and much larger than ever. We also know that CMML treatment approval looks likely in Australia.
Taran can do nothing to meet the demand for shares.
Well, you are correct there are a ton of doses that were in production, but they are a year or two old and one would wonder when they will expire and are worthless. So again, Lenz IP no longer exists with HGENQ. HGENQ is a shell company. It has zero IP and does not manufacture. So really HGENQ has nothing unless something major happens and that is total speculation
I don't see how anyone could say that Humanigen has nothing to do with lenz. How much of the product in the pipeline does Taran own?
"I definitely could have blended right in with those guys."
In fact, believe it or not, I love to sing in choirs, and some of 'John's Boys' heard some of my country covers, and wanted me to join the group. I declined, because they wanted to re-imagine the choir, and become the ChippenWales.
Well, I did say, believe it, or not.
Yes, lens is out of our hands now as we just own an empty shell at this point. Hopefully a nice reverse merger comes in here down the road.
You are welcome for the reminder. Keep in mind, right now HGENQ does not own Lenz and has nothing to do with Lenz. Maybe you should take your Lenz thoughts and comments to the Taran message board, because they own the drug and keep this board about HGENQ
I initiated this thread by focusing on lenzilumab's strong binding affinity and slow off-rate. I think Ivermectin can be a useful therapeutic against covid (it seems to actually bind the covid spike protein), instead of binding GM-CSF. But it seems that as soon as Ivermectin is ceased, all the symptoms patients were suffering come roaring back. It's just an issue I would like to know more about, if regulators continue to keep lenzilumab on the shelf.
Additionally, there is an issue regarding significantly reduced energy levels. That affects me, and I've got a couple acres of land I've got to maintain this spring. I thought it was my being lazy, progressing to just becoming lazier. But this is now ridiculous, and even somewhat debilitating. That's another reason I want to look into this subject. I had already practically self-diagnosed myself as having Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Symptoms can include problems thinking and concentrating, which I try to alleviate with staying engaged here (just don't make me read another 10-Q, or anything else from a bankruptcy court filing), and practically becoming house-bound (but I've always been a homebody).
Anyway, thank you for letting me know that Humanigen doesn't own the lenz IP. I don't anticipate that will adversely impact the safety and efficacy of lenz. Nor do I think it will result in one less short share being recalled. When that happens, I might even get to enjoy a curative dose of adrenaline!
It doesn't matter how they benefit from owning the IP, they own it and we don't
Both Sanofi and Novavax have been tending to details regarding Beneficial Ownership Statements.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&owner=include&count=40&hidefilings=0
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001000694&owner=exclude
How does it benefit Taran to own the IP to a drug that has a strong binding affinity (25 pM) and a slow off-rate?
And HGENQ no longer owns the IP
For further study:
"Lenzilumab is a novel Humaneered® anti-human GM-CSF monoclonal antibody that binds directly to the GM-CSF and blocks further signalling through its receptor. It also showed strong binding affinity (25 pM) and a slow off-rate
https://link.springer.com/article/10.1007/s10787-021-00903-x
Ivermectin, and it's binding of the spike protein
In my initial reply to your post, I failed to acknowledge the first clause in your question. The answer, despite my earlier language in an unrelated post, is that, yes, all is well with me.
However, someone I care about is having some health issues, and I wanted her to see the videos in a couple of my posts. She had told me that she has had some boosters, following a Pfizer vaccine. I have never had a post rejected on this site, AND blocked on X. But, there's a first time for everything. So I had to email the videos to her, and hope that she can open the videos from her email, or that she finds those videos in other of my postings here.
You also expressed some question about Humanigen's right to use lenz. And I see others here also concerned about our future.
For years, I have talked about the "script" written in our company's history. In 2015, as now, the company was forced into a CH11 bankruptcy, just as we were again forced to do. And too many shareholders are failing to continue looking to our past, to project our future. This wasn't The End of the company in 2015, and it isn't The End of the company now, either.
Shareholders need to realize that Humanigen remains on track toward accomplishing their goals. If there has been a change, I think we may see management rely more on foreign regulatory approval. Certainly, we are seeing the British parliament address issues such as excess deaths from mRNA vaccines. This has got to force the MHRA to abandon the status quo, and to consider granting approval of lenz to treat covid.
Other treatments could even capitalize on plant-based alternatives to controlling cytokine release syndrome.
https://www.nasdaq.com/press-release/gb-sciences-targets-covid-19-treatment-as-omicron-variant-arrives-2021-12-06
I think we may be in an ETF with them (but don't ask me to explain that). All I could do was to buy a small number shares in the company.
Finally, to me, there was an unknown distinction between SAR-S CoV-2 coronavirus in nucleocapsid proteins, caused by the virus, versus covid spike proteins caused by the mRNA vaccines. I really hope that a study has been done focused on the reduction of nucleocapsid covid proteins after administering lenz.
The only source I have for this observation is Bret Weinstein. I've hear him comment about the Chinese immigrants in various interviews, and you can hear what he tells Joe Rogan from the 4:05 minute mark.
MP Andrew Bridgen addresses British Parliament on the issue of excess deaths due to mRNA vaccines.
At the 7:30 minute mark, he quotes an expert opinion that the cause of these excess deaths has to be the experimental mRNA vaccines.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43428
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |